Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980, the company maintains some laboratory capability in Corvallis, Oregon. As of 2014, the company does not commercialize any approved drug. As of 2008, Sarepta has 170 issued medical patents, and over 150 patents pending. The company changed its name from AVI BioPharma and stock symbol from AVII in July 2012 to Sarepta Therapeutics and SRPT respectively.
At its founding in 1980, the company was named AntiVirals, Inc. After occupying several research laboratory spaces in Corvallis, the company opened a production laboratory in Corvallis, Oregon, in February 2002 and was renamed AVI BioPharma Inc. The company made headlines in 2003 when it announced work on treatments for severe acute respiratory syndrome (SARS) and the West Nile virus. In July 2009, the company announced they would move their headquarters from Portland, Oregon, north to Bothell, Washington, near Seattle. At that time the company led by president and CEO Leslie Hudson had 83 employees and quarterly revenues of $3.2 million. AVI had yet to turn a profit nor developed any commercial products as of July 2009. The company lost $19.7 million in the second quarter of 2009, and then won a $11.5 million contract with the U.S. Department of Defense's Defense Threat Reduction Agency in October 2009. By this time the company had completed its headquarters move to Bothell.
In 2012 the company moved a second time, to Cambridge, Massachusetts. At the time, CEO Chris Garabedian indicated the move was motivated by the need to recruit expertise in rare diseases. The Corvallis laboratory facility was closed in 2016.
Its primary products are Morpholino oligomers (PMOs), synthetic nucleic acid analogs that were conceived of by James Summerton and invented by Summerton with Dwight Weller, and are being developed under the name NeuGene Antisense. Since morpholino oligomers can form sequence-specific double-stranded complexes with RNA they are suitable use in antisense therapy. In one application, translation blocking, a morpholino oligomer binds to messenger RNA produced by a known disease-causing gene to prevent it from being translated into protein. Morpholinos have been tested for a wide range of applications including prevention of cardiac restenosis after angioplasty, treatment of coronary artery bypass grafts, treatment of polycystic kidney disease, redirection of drug metabolism, Duchenne muscular dystrophy (DMD), and infectious diseases. Their greatest success thus far has been in DMD and as antiviral agents.
The Morpholino drug eteplirsen, targeting exon 51 of the dystrophin mRNA, has been approved as a human therapeutic by the FDA in 2016 and clinical trials for Morpholinos targeting other exons are ongoing. Morpholinos have been used in preclinical studies to inhibit replication of a broad range of viruses, including influenza, West Nile Virus, SARS, Hepatitis C, dengue fever, Ebola and Calicivirus, all of which are single stranded RNA viruses. They are in advanced development for prevention and treatment of Ebola and Marburg viruses. In March 2013, the Company announced positive results from a non-human primate study of AVI-7288, the drug candidate for treatment of Marburg virus infection. The results showed that intramuscular administration of AVI-7288 resulted in survival rates up to 100 percent in monkeys exposed to this fatal virus. These results are similar to those in previous studies when the drug was given by intravenous injection.
In addition to development of Morpholinos as therapeutics, AVI has conducted six human trials for colorectal and pancreatic cancers using their cancer vaccine AVICINE.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-01 | Future report Set alerts | |
Q2 2022 | 2022-08-02 | -2.65 | -2.65 |
Q1 2022 | 2022-05-04 | -1.20 | -1.20 |
Q4 2021 | 2022-03-01 | -1.42 | -1.42 |
Q3 2021 | 2021-11-03 | -0.60 | -0.60 |
Q2 2021 | 2021-08-04 | -1.02 | -1.02 |
Q1 2021 | 2021-05-05 | -2.10 | -2.10 |
Q4 2020 | 2021-03-01 | -2.40 | -2.40 |
Q3 2020 | 2020-11-05 | 0.00 | 0.00 |
Q2 2020 | 2020-08-05 | -1.93 | -1.93 |
2016-06-27 | Reiterated Rating | Robert W. Baird | Outperform | $23.00 |
2016-06-27 | Reiterated Rating | William Blair | Market Perform | |
2016-06-25 | Reiterated Rating | Jefferies Group | Underperform | $7.00 |
2016-06-22 | Reiterated Rating | Wedbush | Outperform | $36.00 |
2016-06-21 | Reiterated Rating | Oppenheimer | Outperform | $60.00 |
2016-06-21 | Reiterated Rating | Oppenheimer Holdings Inc. | Outperform | $60.00 |
2016-06-10 | Reiterated Rating | Robert W. Baird | Buy | |
2016-06-09 | Upgrade | Piper Jaffray | Underweight to Neutral | |
2016-06-09 | Upgrade | Piper Jaffray Cos. | Underweight to Neutral | |
2016-06-08 | Reiterated Rating | WBB Securities | Buy | $40.00 |
2016-06-07 | Upgrade | Wedbush | Neutral to Outperform | $14.00 to $36.00 |
2016-06-07 | Reiterated Rating | Janney Montgomery Scott | Hold | |
2016-06-07 | Reiterated Rating | Cowen and Company | Hold | |
2016-06-04 | Reiterated Rating | Piper Jaffray | Sell | $6.00 |
2016-06-03 | Reiterated Rating | JMP Securities | Sell | $10.00 |
2016-06-03 | Reiterated Rating | Oppenheimer | Outperform | $60.00 |
2016-06-03 | Reiterated Rating | RBC Capital | Hold | $5.00 |
2016-06-03 | Reiterated Rating | Robert W. Baird | Outperform | $23.00 |
2016-06-03 | Reiterated Rating | Leerink Swann | Underperform | $5.00 |
2016-06-03 | Reiterated Rating | Royal Bank Of Canada | Hold | $5.00 |
2016-06-02 | Reiterated Rating | Jefferies Group | Sell | $7.00 |
2016-06-01 | Reiterated Rating | Wedbush | Outperform | $14.00 to $23.00 |
2016-05-27 | Reiterated Rating | SunTrust | Reduce | |
2016-05-27 | Reiterated Rating | SunTrust Banks Inc. | Reduce | |
2016-05-26 | Reiterated Rating | Robert W. Baird | Outperform | $23.00 |
2016-05-26 | Reiterated Rating | Oppenheimer | Outperform | $60.00 |
2016-05-26 | Reiterated Rating | Leerink Swann | Sell | |
2016-05-26 | Reiterated Rating | Janney Montgomery Scott | Hold | |
2016-05-26 | Reiterated Rating | Piper Jaffray | Sell | |
2016-05-26 | Reiterated Rating | Cowen and Company | Hold | |
2016-05-26 | Reiterated Rating | RBC Capital | Sector Perform | $5.00 |
2016-05-25 | Reiterated Rating | Wedbush | Neutral | $14.00 |
2016-05-08 | Reiterated Rating | Robert W. Baird | Buy | |
2016-05-06 | Reiterated Rating | Jefferies Group | Sell | $7.00 |
2016-05-05 | Downgrade | Ladenburg Thalmann | Market Perform to Underperform | $13.00 to $5.00 |
2016-05-02 | Upgrade | Oppenheimer | Market Perform to Outperform | $60.00 |
2016-05-02 | Downgrade | Leerink Swann | Market Perform to Underperform | $13.00 to $5.00 |
2016-05-02 | Reiterated Rating | WBB Securities | Strong-Buy | $40.00 |
2016-05-02 | Downgrade | Leerink Partner | Market Perform to Underperform | |
2016-04-29 | Downgrade | Jefferies Group | Hold to Underperform | $7.00 to $13.80 |
2016-04-26 | Downgrade | Piper Jaffray | Neutral to Underweight | $15.00 to $6.00 |
2016-04-26 | Lower Price Target | Jefferies Group | Hold to Hold | $14.00 to $7.00 |
2016-04-26 | Downgrade | SunTrust | Neutral to Reduce | $14.00 to $4.00 |
2016-04-26 | Downgrade | Oppenheimer | Outperform to Market Perform | |
2016-04-26 | Reiterated Rating | Janney Montgomery Scott | Neutral | $15.00 |
2016-04-26 | Reiterated Rating | WBB Securities | Buy | $40.00 |
2016-04-24 | Reiterated Rating | Needham & Company LLC | Buy | $53.00 to $20.00 |
2016-04-23 | Reiterated Rating | Cowen and Company | Market Perform | |
2016-04-23 | Reiterated Rating | RBC Capital | Hold | |
2016-04-23 | Reiterated Rating | Robert W. Baird | Buy | $47.00 to $23.00 |
2016-04-22 | Boost Price Target | RBC Capital | Sector Perform | $7.50 to $14.00 |
2016-04-21 | Reiterated Rating | Piper Jaffray | Neutral to Hold | |
2016-04-21 | Reiterated Rating | Leerink Swann | Hold | $13.00 |
2016-04-21 | Downgrade | Wedbush | Outperform to Neutral | $14.00 to $32.00 |
2016-04-21 | Downgrade | William Blair | Outperform to Market Perform | |
2016-04-21 | Reiterated Rating | Oppenheimer | Outperform to Buy | $60.00 |
2016-04-20 | Initiated Coverage | Janney Montgomery Scott | Neutral | $19.00 |
2016-04-19 | Reiterated Rating | Jefferies Group | Hold | $14.00 |
2016-04-17 | Reiterated Rating | Cowen and Company | Hold | |
2016-04-06 | Boost Price Target | Oppenheimer | Outperform | $45.00 to $60.00 |
2016-03-30 | Reiterated Rating | WBB Securities | Buy | $40.00 |
2016-03-23 | Downgrade | JMP Securities | Market Perform to Underperform | $10.00 |
2016-03-22 | Reiterated Rating | Jefferies Group | Hold | $14.00 |
2016-03-22 | Reiterated Rating | Needham & Company LLC | Buy | $53.00 |
2016-03-22 | Reiterated Rating | Robert W. Baird | Outperform | $47.00 |
2016-03-14 | Reiterated Rating | Jefferies Group | Hold | $14.00 |
2016-03-11 | Reiterated Rating | Oppenheimer | Outperform | $45.00 |
2016-03-10 | Reiterated Rating | Piper Jaffray | Hold | |
2016-03-09 | Reiterated Rating | Wedbush | Outperform | $32.00 |
2016-03-01 | Lower Price Target | Needham & Company LLC | Buy | $55.00 to $53.00 |
2016-02-27 | Reiterated Rating | Cowen and Company | Hold | |
2016-02-26 | Reiterated Rating | Wedbush | Outperform | $32.00 |
2016-02-10 | Reiterated Rating | Oppenheimer | Outperform | $45.00 |
2016-02-08 | Reiterated Rating | Piper Jaffray | Hold | |
2016-02-01 | Reiterated Rating | Wedbush | Outperform | $32.00 to $56.00 |
2016-01-19 | Lower Price Target | SunTrust | Neutral | $20.00 |
2016-01-19 | Reiterated Rating | Robert W. Baird | Outperform | $47.00 |
2016-01-19 | Reiterated Rating | Wedbush | Outperform | $56.00 |
2016-01-19 | Downgrade | RBC Capital | Outperform to Sector Perform | $62.00 to $15.00 |
2016-01-15 | Reiterated Rating | Leerink Swann | Hold | |
2016-01-15 | Reiterated Rating | Oppenheimer | Buy | $45.00 |
2016-01-15 | Reiterated Rating | Needham & Company LLC | Buy | |
2016-01-15 | Reiterated Rating | Cowen and Company | Hold | |
2016-01-15 | Downgrade | Piper Jaffray | Overweight to Neutral | $15.00 |
2016-01-05 | Reiterated Rating | Piper Jaffray | Overweight | $48.00 |
2015-11-28 | Reiterated Rating | Needham & Company LLC | Buy | |
2015-11-25 | Reiterated Rating | Robert W. Baird | Outperform | $47.00 |
2015-11-25 | Reiterated Rating | Jefferies Group | Hold | $28.00 to $38.00 |
2015-11-22 | Reiterated Rating | Needham & Company LLC | Buy | $55.00 |
2015-11-22 | Reiterated Rating | WBB Securities | Buy | $40.00 |
2015-11-20 | Reiterated Rating | Oppenheimer | Outperform | $45.00 |
2015-11-11 | Reiterated Rating | Cowen and Company | Market Perform | |
2015-11-08 | Reiterated Rating | Needham & Company LLC | Buy | $50.00 |
2015-11-08 | Reiterated Rating | Roth Capital | Buy | $50.00 |
2015-11-06 | Lower Price Target | Leerink Swann | Market Perform | $33.00 to $27.00 |
2015-10-23 | Initiated Coverage | Bank of America | Buy | $49.00 |
2015-10-23 | Initiated Coverage | Bank of America Corp. | Buy | $49.00 |
2015-10-22 | Initiated Coverage | Jefferies Group | Hold | $28.00 to $28.00 |
2015-10-17 | Reiterated Rating | Oppenheimer | Buy | $45.00 |
2015-10-16 | Reiterated Rating | Roth Capital | Buy | $50.00 |
2015-10-09 | Reiterated Rating | Oppenheimer | Outperform | $45.00 |
2015-10-05 | Reiterated Rating | Cowen and Company | Market Perform | |
2015-10-04 | Reiterated Rating | Piper Jaffray | Buy | |
2015-10-02 | Reiterated Rating | Robert W. Baird | Buy | $47.00 |
2015-10-02 | Upgrade | Wedbush | Neutral to Outperform | $56.00 |
2015-10-01 | Reiterated Rating | Needham & Company LLC | Buy | $38.00 to $55.00 |
2015-10-01 | Reiterated Rating | Roth Capital | Buy | $50.00 |
2015-09-30 | Reiterated Rating | William Blair | Buy | |
2015-09-30 | Reiterated Rating | RBC Capital | Outperform | $62.00 |
2015-09-28 | Reiterated Rating | Oppenheimer | Buy | $45.00 |
2015-09-03 | Reiterated Rating | Roth Capital | Buy | $50.00 |
2015-09-01 | Boost Price Target | SunTrust | Neutral | $33.00 to $36.00 |
2015-09-01 | Boost Price Target | Susquehanna | Neutral | $33.00 to $36.00 |
2015-08-26 | Reiterated Rating | Cowen and Company | Hold | |
2015-08-26 | Reiterated Rating | William Blair | Buy | $43.00 |
2015-08-26 | Reiterated Rating | Robert W. Baird | Buy | $47.00 |
2015-08-26 | Upgrade | RBC Capital | Sector Perform to Outperform | $35.00 to $62.00 |
2015-08-26 | Reiterated Rating | Roth Capital | Buy | $45.00 to $50.00 |
2015-08-24 | Upgrade | Piper Jaffray | Neutral to Overweight | $28.00 to $48.00 |
2015-08-20 | Reiterated Rating | Roth Capital | Buy | $50.00 to $45.00 |
2015-08-13 | Reiterated Rating | WBB Securities | Buy | $35.00 to $40.00 |
2015-08-07 | Reiterated Rating | Cowen and Company | Hold | |
2015-08-07 | Reiterated Rating | Robert W. Baird | Buy | $34.00 to $47.00 |
2015-08-07 | Reiterated Rating | RBC Capital | Hold | $20.00 to $35.00 |
2015-08-07 | Boost Price Target | Wedbush | Neutral | $25.00 to $31.00 |
2015-08-07 | Downgrade | SunTrust | Buy to Neutral | $33.00 |
2015-08-06 | Reiterated Rating | Piper Jaffray | Hold | |
2015-08-05 | Reiterated Rating | Roth Capital | Buy | $45.00 |
2015-07-20 | Reiterated Rating | Roth Capital | Buy | |
2015-06-30 | Reiterated Rating | Roth Capital | Buy | $45.00 |
2015-06-30 | Reiterated Rating | Oppenheimer | Buy | $45.00 to $28.18 |
2015-06-30 | Reiterated Rating | Robert W. Baird | Buy | $34.00 |
2015-06-18 | Reiterated Rating | SunTrust | Buy | $33.00 |
2015-06-09 | Set Price Target | RBC Capital | Hold | $20.00 |
2015-06-09 | Reiterated Rating | Roth Capital | Buy | $45.00 |
2015-05-23 | Reiterated Rating | Deutsche Bank | Hold | $24.00 |
2015-05-23 | Reiterated Rating | William Blair | Outperform | $34.00 to $43.00 |
2015-05-23 | Reiterated Rating | Piper Jaffray | Neutral | $20.00 |
2015-05-23 | Reiterated Rating | Deutsche Bank AG | Hold | $24.00 |
2015-05-22 | Reiterated Rating | WBB Securities | Strong-Buy | $25.00 to $35.00 |
2015-05-21 | Downgrade | Bank of America | Buy to Neutral | $20.00 to $28.00 |
2015-05-20 | Set Price Target | Oppenheimer | Buy | $45.00 |
2015-05-20 | Reiterated Rating | Cowen and Company | Neutral | |
2015-05-20 | Set Price Target | Robert W. Baird | Buy | $20.00 to $34.00 |
2015-05-20 | Boost Price Target | Wedbush | Neutral | $16.00 to $25.00 |
2015-05-20 | Upgrade | Canaccord Genuity | Hold to Buy | $16.00 to $30.00 |
2015-05-20 | Upgrade | SunTrust | Neutral to Buy | $14.00 to $33.00 |
2015-05-20 | Boost Price Target | RBC Capital | Sector Perform | $15.00 to $20.00 |
2015-05-20 | Boost Price Target | Roth Capital | Buy | $22.00 to $45.00 |
2015-05-07 | Reiterated Rating | Needham & Company LLC | Buy | $38.00 |
2015-05-06 | Upgrade | Robert W. Baird | Neutral to Outperform | $16.00 to $20.00 |
2015-04-07 | Upgrade | Roth Capital | Buy | $22.00 |
2015-04-07 | Upgrade | SunTrust | Neutral | $14.00 |
2015-04-01 | Set Price Target | Oppenheimer | Buy | $45.00 |
2015-04-01 | Set Price Target | Robert W. Baird | Hold | $16.00 |
2015-04-01 | Reiterated Rating | RBC Capital | Positive | |
2015-03-02 | Lower Price Target | Needham & Company LLC | Buy | $52.00 to $38.00 |
2015-02-27 | Reiterated Rating | Canaccord Genuity | Hold | $16.00 |
2015-02-27 | Reiterated Rating | Robert W. Baird | Neutral | |
2015-02-27 | Downgrade | Cowen and Company | Outperform to Market Perform | |
2015-02-20 | Set Price Target | Roth Capital | Buy | $22.00 |
2015-02-17 | Upgrade | Bank of America | Neutral to Buy | $19.00 to $21.00 |
2015-02-04 | Initiated Coverage | SunTrust | Neutral | |
2015-01-27 | Upgrade | Northland Securities | Market Perform to Outperform | $3.00 |
2015-01-22 | Initiated Coverage | RBC Capital | Sector Perform | $15.00 |
2015-01-20 | Downgrade | Wedbush | Outperform to Neutral | $16.00 |
2015-01-15 | Set Price Target | Cowen and Company | Buy | $19.00 |
2015-01-15 | Reiterated Rating | WBB Securities | Buy | |
2015-01-08 | Initiated Coverage | Canaccord Genuity | Hold | |
2015-01-07 | Set Price Target | Roth Capital | Buy | $22.00 |
2014-11-26 | Upgrade | WBB Securities | Buy to Strong-Buy | $25.00 |
2014-11-03 | Initiated Coverage | Roth Capital | Buy | |
2014-10-31 | Reiterated Rating | Robert W. Baird | Positive | |
2014-10-28 | Downgrade | Robert W. Baird | Outperform to Neutral | $53.00 to $21.00 |
2014-10-27 | Downgrade | Stifel Nicolaus | Buy to Hold | |
2014-10-27 | Downgrade | JMP Securities | Outperform to Market Perform | |
2014-10-07 | Reiterated Rating | Credit Suisse | Outperform | |
2014-10-07 | Reiterated Rating | Credit Suisse Group AG | Outperform | |
2014-09-24 | Initiated Coverage | Credit Suisse | Outperform | $36.00 |
2014-08-19 | Initiated Coverage | Cowen and Company | Outperform | $44.00 |
2014-07-31 | Initiated Coverage | Oppenheimer | Outperform | $45.00 |
2014-07-30 | Reiterated Rating | Deutsche Bank | Positive | |
2014-07-29 | Boost Price Target | WBB Securities | Speculative Buy to Buy | $25.00 |
2014-07-22 | Initiated Coverage | Bank of America | Neutral | $27.00 |
2014-05-22 | Initiated Coverage | Roth Capital | Buy | $52.00 |
2014-04-22 | Boost Price Target | Deutsche Bank | Positive to Hold | $17.00 to $35.00 |
2014-04-22 | Upgrade | Citigroup Inc. | Sell to Neutral | |
2014-04-21 | Upgrade | Canaccord Genuity | Hold to Buy | $27.00 to $63.00 |
2014-04-21 | Upgrade | JMP Securities | Market Perform to Outperform | $54.00 |
2014-04-21 | Reiterated Rating | Needham & Company LLC | Buy | $36.00 to $52.00 |
2014-04-21 | Upgrade | William Blair | Market Perform to Outperform | $63.00 |
2014-04-14 | Initiated Coverage | Sidoti | Buy | |
2014-03-04 | Boost Price Target | Canaccord Genuity | Hold | $25.00 to $27.00 |
2014-01-27 | Downgrade | JMP Securities | Outperform to Market Perform | $25.00 |
2014-01-24 | Boost Price Target | Canaccord Genuity | $20.00 to $25.00 | |
2014-01-21 | Upgrade | Needham & Company LLC | Hold to Buy | $36.00 |
2014-01-06 | Downgrade | Citigroup Inc. | Neutral to Sell | $13.00 |
2013-12-23 | Upgrade | Piper Jaffray | Underweight to Neutral | $19.55 to $20.00 |
2013-12-06 | Downgrade | Canaccord Genuity | Buy to Hold | $20.00 |
2013-11-26 | Upgrade | WBB Securities | Sell to Speculative Buy | $9.00 to $19.00 |
2013-11-13 | Lower Price Target | Canaccord Genuity | Buy | $20.00 |
2013-11-12 | Lower Price Target | Robert W. Baird | Outperform | $63.00 to $22.00 |
2013-11-12 | Lower Price Target | Leerink Swann | Market Perform | $44.00 to $17.00 |
2013-11-12 | Lower Price Target | Wedbush | Outperform | $60.00 to $45.00 |
2013-11-12 | Downgrade | Deutsche Bank | Buy to Hold | $71.00 to $17.00 |
2013-11-12 | Lower Price Target | FBR & Co. | Market Perform | $48.00 to $20.00 |
2013-11-12 | Downgrade | Janney Montgomery Scott | Neutral to Sell | |
2013-11-12 | Downgrade | William Blair | Outperform to Market Perform | |
2013-11-12 | Downgrade | Needham & Company LLC | Buy to Hold | |
2013-11-12 | Downgrade | Piper Jaffray | Overweight to Underweight | $58.00 to $20.00 |
2013-10-30 | Initiated Coverage | FBR & Co. | Market Perform | $48.00 |
2013-10-03 | Reiterated Rating | Robert W. Baird | Buy | |
2013-09-26 | Reiterated Rating | Canaccord Genuity | Positive to Buy | $65.00 |
2013-09-23 | Reiterated Rating | Needham & Company LLC | Positive | |
2013-09-20 | Upgrade | Piper Jaffray | Neutral to Overweight | |
2013-09-20 | Upgrade | Deutsche Bank | Hold to Buy | $45.00 to $71.00 |
2013-04-22 | Initiated | Needham | Buy | $57 |
2013-04-04 | Initiated | Robert W. Baird | Outperform | $63 |
2013-04-03 | Initiated | Robert W. Baird | Outperform | $63 |
2013-03-08 | Reiterated | Burrill Institutional Research | Mkt Outperform | $54 to $39 |
2012-11-26 | Initiated | Burrill Institutional Research | Mkt Outperform | $54 |
2012-09-12 | Downgrade | WBB Securities | Hold to Sell | $8 to $9 |
2012-08-09 | Initiated | WBB Securities | Hold | $8 |
2016-06-27 | Reiterated Rating | Robert W. Baird | Outperform | $23.00 |
2016-06-27 | Reiterated Rating | William Blair | Market Perform | |
2016-06-25 | Reiterated Rating | Jefferies Group | Underperform | $7.00 |
2016-06-22 | Reiterated Rating | Wedbush | Outperform | $36.00 |
2016-06-21 | Reiterated Rating | Oppenheimer | Outperform | $60.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In SRPT 267 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
Vanguard Group, Inc | 8.09M |
HENDERSON GROUP PLC | 6.48M |
BlackRock Inc. | 5.34M |
venBio Select Advisor LLC | 3.17M |
EcoR1 Capital, LLC | 3.00M |
WELLINGTON MANAGEMENT CO LLP | 2.56M |
FMR LLC | 2.55M |
SANDS CAPITAL MANAGEMENT, LLC | 2.48M |
BlackRock Fund Advisors | 2.26M |
STATE STREET CORP | 1.93M |
Camber Capital Management LLC | 1.50M |
GOLDMAN SACHS GROUP INC | 1.45M |
BlackRock Institutional Trust Company, N.A. | 1.31M |
ALKEON CAPITAL MANAGEMENT LLC | 1.23M |
PRICE T ROWE ASSOCIATES INC /MD/ | 1.22M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
Barry Richard | 7.93% (3245432) | SRPT / TELK / |
Hudson Leslie Former CEO | 0.94% (384559) | SRPT / |
INGRAM DOUGLAS S President & CEO | 0.93% (382058) | AGN / SRPT / |
BEHRENS M KATHLEEN | 0.28% (116534) | SRPT / |
Kaye Edward M. MD SVP & Chief Medical Officer | 0.17% (71229) | CYTK / SRPT / |
BOYLE J DAVID II CEO | 0.17% (70282) | SRPT / |
CHASE ANTHONY R | 0.16% (67194) | APC / SRPT / WES / |
Price Ben Gil | 0.10% (42830) | SRPT / |
Mahatme Sandesh Senior Vice President, CFO | 0.10% (42661) | AGLE / FLXN / SRPT / |
Howton David T SVP, General Counsel | 0.08% (31118) | SRPT / |
Christopher Nishan Garabedian | 0.07% (29552) | SRPT / |
Ruff Shamim SVP, Regulatory Affairs & Qual | 0.07% (28809) | SRPT / |
Cumbo Alexander VP, Head of Commercial | 0.06% (25325) | SRPT / |
Aphale Jayant SVP Technical Operations | 0.03% (12255) | SRPT / |
Wigzell Hans Lennart Rudolf | 0.02% (10084) | SRPT / |
Goolsbee William Alden | 0.02% (8166) | SRPT / |
JACOBSEN MICHAEL A VP of Finance and PAO | 0.02% (7500) | OMER / SRPT / |
HODGMAN JOHN | 0.02% (6333) | IMMR / ITMN / SRPT / |
Nicaise Claude | 0.01% (5418) | SRPT / |
BONNEY MICHAEL W | 0.01% (3418) | ALNY / CBST / CELG / HQH / HQL / NPSP / SRPT / |